128 results
Page 2 of 7
6-K
EX-99.1
7c0e7z40 vbq
6 Oct 16
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
12:00am
6-K
wjkj4e 3rpchhb9nmxpk
20 Sep 16
Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
12:00am
6-K
EX-99.1
7vg sdjpz6zpl7e17
20 Sep 16
Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
12:00am
6-K
EX-99.1
ixnxvdlspyx0rm7s6h8
12 Apr 16
Teva to Present Data Highlighting Company’s Pipeline in Neurological Disorders at 68th AAN Annual Meeting
12:00am
6-K
EX-99.1
7l64b4ry1xipketrfy3j
30 Sep 15
IMPORTANT NEW DATA FROM TEVA’S TEV-48125 PHASE 2b MIGRAINE PROGRAM PUBLISHED INLANCET NEUROLOGYIN BACK-TO-BACK ARTICLES
12:00am
6-K
EX-99.1
1na l0sne
28 Sep 15
Teva Presents New Reslizumab Data at European Respiratory Society (ERS) International Congress 2015
12:00am
6-K
EX-99.1
nsn2u1
8 Sep 15
Live Filing
12:00am
425
e6mtvbtivxhg x6j
21 Apr 15
Business combination disclosure
12:00am
6-K
EX-99.1
zjgfc7j8i
23 Mar 15
Live Filing
12:00am
6-K
EX-99.1
gx3q0zdos0mgkqp04nc
25 Feb 15
Live Filing
12:00am
6-K
EX-99.1
fh2swv1
24 Feb 15
TEVA ANNOUNCES POSITIVE RESULTS FOR TEV-48125 IN PHASE IIb CHRONIC MIGRAINE STUDY MEETING PRIMARY AND SECONDARY ENDPOINTS
12:00am
6-K
dob0 niuf
24 Feb 15
TEVA ANNOUNCES POSITIVE RESULTS FOR TEV-48125 IN PHASE IIb CHRONIC MIGRAINE STUDY MEETING PRIMARY AND SECONDARY ENDPOINTS
12:00am
6-K
EX-99.1
sx2ctlqb nbrdb9iwki4
23 Feb 15
Live Filing
12:00am
6-K
EX-99.1
7iz4fwn6uwbdaca
19 Dec 14
First Waterless Nasal Allergy Spray Approved for Children as Young as Four Years of Age
12:00am
6-K
EX-99.1
sxyubv02mhi vtgvo
18 Nov 14
Live Filing
12:00am
6-K
EX-99.1
cdeu8o8
7 Nov 14
Live Filing
12:00am
6-K
EX-99.1
x26d1kd4ex g3
7 Nov 14
Late Stage Data to be Presented at ACAAI 2014
12:00am
6-K
2pqz67nkai4qw3s97hh
30 Oct 14
Current report (foreign)
12:00am